This patented technology introduces a unified electrochemical platform for purifying and recycling biofluids in biomanufacturing. Traditional purification processes rely on multiple discrete unit operations including chromatography, filtration, and chemical treatment, which account for fifty to eighty percent of total production costs and generate substantial waste. The Problem Current biomanufacturing purification faces four critical challenges: high cost of Protein A affinity chromatography with resin expenses exceeding ten thousand dollars per liter and limited lifetime of one to two hundred cycles; excessive buffer consumption of fifty to one hundred liters per liter of product generating significant waste; single-use disposal of cell culture media representing material waste and lost value; and complex multi-step processes for endotoxin removal increasing operational burden. Our Solution This invention overcomes these limitations through an integrated electrochemical approach combining activation, selective separation, and buffer regeneration in a single modular system. The core innovation leverages dimensionally stable anodes with iridium-tantalum oxide coatings, integrated membrane stacks combining electrodialysis ultrafiltration and nanofiltration, and model predictive control with inline process analytical technology sensors. Key Technical Advantages Superior impurity removal achieves greater than ninety-five percent clearance of lactate ammonia host cell proteins DNA and endotoxins through combined electrochemical oxidation electrocoagulation and electroflotation mechanisms. High product recovery maintains greater than ninety percent yield of target molecules including monoclonal antibodies recombinant proteins and viral vectors through gentle electrochemical conditions and optimized flow dynamics. Energy efficiency of fifteen to forty kilowatt-hours per cubic meter processed represents thirty percent reduction versus traditional chromatography while eliminating eighty percent of chemical waste and seventy percent of water consumption. Performance Metrics The system demonstrates impurity removal exceeding ninety-five percent product recovery above ninety percent and processing costs of zero point two two to zero point four five dollars per liter versus zero point sixty to one point twenty dollars for traditional methods. Cleaning-in-place cycles complete in sixty-five minutes compared to one hundred twenty plus minutes for chromatography systems. Media recycling rates of seventy to eighty-five percent enable five to ten fold extension of culture media lifetime. Target Applications Cell culture media recycling for CHO and other production cell lines removing metabolic waste while replenishing nutrients. Monoclonal antibody purification replacing or augmenting Protein A chromatography with lower cost and higher sustainability. Fermentation broth clarification separating cells and debris while recovering product and regenerating media components. Buffer regeneration through electrodialysis enabling reuse of purification buffers with ninety percent salt recovery. Intellectual Property Status Patent application pending with ten claims covering system method and use configurations. International Patent Classification: C12M 1/00; C02F 1/46; B01D 61/00; C07K 1/36; A61K 39/395. Inventor: Artem G. Teplov, ORCID: 0009-0000-0049-5232. Commercial Opportunity The global bioprocessing market exceeds one hundred billion dollars with purification representing the largest cost component. Our platform addresses critical pain points for biopharma manufacturers and CDMOs: forty to sixty percent cost reduction versus chromatography eighty percent reduction in chemical waste seventy percent lower water consumption and seamless scalability from laboratory to commercial production. Licensing Framework Non-exclusive evaluation license available for full technical documentation working examples and manufacturing specifications. Commercial licensing negotiable based on application domain territory and production volume. Open to joint R&D partnerships pilot deployment collaborations and equity investment in scale-up ventures. Impact Alignment This technology directly supports UN Sustainable Development Goals three (Good Health), nine (Industry & Innovation), and twelve (Responsible Consumption) by enabling cleaner more efficient and sustainable biomanufacturing of life-saving therapeutics. For licensing inquiries technical collaboration or investment discussions: Email: Teplov.a.g@gmail.com